Table 3.
Sensitivity analysis for associations between PM2.5 and NO2 as well as deterioration in pre-end-stage renal disease (pre-ESRD) patients.
| Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) a | p values | HR (95% CI) b | p values | HR (95% CI) c | p values | |
| Excluding eGFR deterioration within 7 days (deterioration: 1,854/Total population: 3,253) | ||||||
| PM2.5 | 1.05 (1.04–1.05) | <0.0001 | 1.12 (1.10–1.13) | <0.0001 | 1.11 (1.09–1.12) | <0.0001 |
| <25.13 | REF | REF | REF | |||
| 25.13–31.44 | 1.14 (1.04–1.25) | 0.0051 | 1.45 (1.25–1.69) | <0.0001 | 1.33 (1.14–1.56) | 0.0004 |
| ≧31.44 | 1.80 (1.64–1.97) | <0.0001 | 3.57 (3.02–4.23) | <0.0001 | 2.82 (2.32–3.43) | <0.0001 |
| NO2 | 1.08 (1.07–1.10) | <0.0001 | 1.15 (1.12–1.18) | <0.0001 | 1.03 (1.00–1.06) | 0.0488 |
| <12.88 | REF | REF | REF | |||
| 12.88–15.00 | 1.08 (0.98–1.19) | 0.1078 | 1.14 (0.99–1.31) | 0.0668 | 1.03 (0.89–1.18) | 0.7203 |
| ≥15.00 | 1.60 (1.46–1.76) | <0.0001 | 2.38 (2.03–2.78) | <0.0001 | 1.47 (1.23–1.77) | <0.0001 |
| Excluding eGFR deterioration within 30 days (deterioration: 1,672/ Total population: 3,007) | ||||||
| PM2.5 | 1.04 (1.03–1.05) | <0.0001 | 1.11 (1.10–1.13) | <0.0001 | 1.11 (1.09–1.12) | <0.0001 |
| <25.13 | REF | REF | REF | |||
| 25.13–31.44 | 1.08 (0.98–1.19) | 0.1218 | 1.43 (1.23–1.67) | <0.0001 | 1.33 (1.14–1.57) | 0.0004 |
| ≥31.44 | 1.65 (1.50–1.82) | <0.0001 | 3.42 (2.87–4.07) | <0.0001 | 2.80 (2.29–3.43) | <0.0001 |
| NO2 | 1.07 (1.05–1.08) | <0.0001 | 1.13 (1.10–1.16) | <0.0001 | 1.02 (0.99–1.04) | 0.3216 |
| <12.88 | REF | REF | REF | |||
| 12.88–15.00 | 1.05 (0.95–1.16) | 0.3298 | 1.12 (0.97–1.29) | 0.1339 | 1.01 (0.87–1.16) | 0.9338 |
| ≥15.00 | 1.45 (1.32–1.60) | <0.0001 | 2.21 (1.88–2.60) | <0.0001 | 1.38 (1.14–1.67) | 0.0009 |
| Excluding eGFR deterioration within 90 days (deterioration: 1,133/ Total population: 2,359) | ||||||
| PM2.5 | 1.05 (1.04–1.06) | <0.0001 | 1.12 (1.10–1.13) | <0.0001 | 1.11 (1.08–1.13) | <0.0001 |
| <25.13 | REF | REF | REF | |||
| 25.13–31.44 | 1.06 (0.94–1.19) | 0.3282 | 1.38 (1.15–1.65) | 0.0006 | 1.27 (1.05–1.54) | 0.0153 |
| ≥31.44 | 1.77 (1.57–1.99) | <0.0001 | 3.52 (2.85–4.33) | <0.0001 | 2.80 (2.20–3.57) | <0.0001 |
| NO2 | 1.07 (1.05–1.09) | <0.0001 | 1.14 (1.11–1.18) | <0.0001 | 1.03 (0.99–1.07) | 0.123 |
| <12.88 | REF | REF | REF | |||
| 12.88–15.00 | 1.02 (0.91–1.15) | 0.7062 | 1.10 (0.93–1.31) | 0.2592 | 0.99 (0.83–1.18) | 0.9194 |
| ≥15.00 | 1.48 (1.32–1.66) | <0.0001 | 2.31 (1.89–2.81) | <0.0001 | 1.44 (1.14–1.80) | 0.0019 |
Model 1: adjustment for age, gender, baseline eGFR stages, county, education, occupation, smoking status, and sport habits.
Model 2: adjustment for age, gender, baseline eGFR stages, county, smoking, diabetes, hypertension, medication usage, and clinical examination index.
Model 3: adjustment for age, gender, baseline eGFR stages, county, smoking, diabetes, hypertension, medication usage, and clinical examination index as well as another air pollutant.